Computational strategies to address therapeutic resistance in estrogen receptor‐positive breast cancer: A narrative review of molecular docking, molecular dynamics simulations, and emerging therapeutic targets
Estrogen receptor‐positive (ER+) breast cancer represents the most common molecular subtype of breast cancer and remains highly responsive to endocrine therapy. However, therapeutic efficacy is frequently compromised by acquired or intrinsic endocrine resistance, particularly through ESR1 mutations, altered recep...